

**Experiment Number:** 99020-03  
**Test Type:** 90-DAY  
**Route:** GAVAGE  
**Species/Strain:** Rat/F 344/N

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

**Test Compound:** Pulegone  
**CAS Number:** 89-82-7

**Date Report Requested:** 10/20/2014  
**Time Report Requested:** 05:19:07  
**First Dose M/F:** NA / NA  
**Lab:** BAT

**C Number:** C99020  
**Lock Date:** 09/27/2002  
**Cage Range:** All  
**Date Range:** All  
**Reasons For Removal:** All  
**Removal Date Range:** All  
**Treatment Groups:** All  
**Study Gender:** Both  
**PWG Approval Date:** NONE

Experiment Number: 99020-03

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: Pulegone

Time Report Requested: 05:19:07

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: BAT

| F 344/N Rat MALE                 | 0 MG/KG | 9.375 MG/KG | 18.75 MG/KG | 37.5 MG/KG | 75 MG/KG  | 150 MG/KG |
|----------------------------------|---------|-------------|-------------|------------|-----------|-----------|
| <b>Disposition Summary</b>       |         |             |             |            |           |           |
| Animals Initially In Study       | 10      | 10          | 10          | 10         | 10        | 10        |
| Early Deaths                     |         |             |             |            |           |           |
| Survivors                        |         |             |             |            |           |           |
| Terminal Sacrifice               | 10      | 10          | 10          | 10         | 10        | 10        |
| Animals Examined Microscopically | 10      | 10          | 10          | 10         | 10        | 10        |
| <b>ALIMENTARY SYSTEM</b>         |         |             |             |            |           |           |
| Esophagus                        | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Intestine Large, Cecum           | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Intestine Large, Colon           | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Intestine Large, Rectum          | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Parasite Metazoan                | 1 (10%) |             |             |            |           |           |
| Intestine Small, Duodenum        | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Intestine Small, Ileum           | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Intestine Small, Jejunum         | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Liver                            | (10)    | (10)        | (10)        | (10)       | (10)      | (10)      |
| Bile Duct, Hyperplasia           |         |             |             |            | 9 (90%)   | 10 (100%) |
| Hepatocyte, Hypertrophy          |         |             |             |            | 10 (100%) | 10 (100%) |
| Hepatocyte, Necrosis, Focal      |         |             |             |            |           | 6 (60%)   |
| Hepatodiaphragmatic Nodule       |         | 2 (20%)     | 2 (20%)     | 2 (20%)    |           |           |
| Inflammation, Chronic Active     | 1 (10%) |             |             | 1 (10%)    | 1 (10%)   | 1 (10%)   |
| Mineralization                   |         |             |             | 1 (10%)    |           | 1 (10%)   |
| Oval Cell, Hyperplasia           |         |             |             |            |           | 10 (100%) |
| Periportal, Fibrosis             |         |             |             |            |           | 10 (100%) |
| Pigmentation                     |         |             |             |            |           | 1 (10%)   |
| Pancreas                         | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Basophilic Focus                 |         |             |             |            |           | 1 (10%)   |
| Salivary Glands                  | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Metaplasia, Squamous, Focal      |         |             |             |            |           | 1 (10%)   |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99020-03

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: Pulegone

Time Report Requested: 05:19:07

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: BAT

| F 344/N Rat MALE                      | 0 MG/KG | 9.375 MG/KG | 18.75 MG/KG | 37.5 MG/KG | 75 MG/KG | 150 MG/KG |
|---------------------------------------|---------|-------------|-------------|------------|----------|-----------|
| Stomach, Forestomach                  | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Stomach, Glandular                    | (10)    | (10)        | (10)        | (10)       | (10)     | (10)      |
| Mineralization                        | 5 (50%) | 3 (30%)     | 5 (50%)     | 2 (20%)    | 3 (30%)  | 9 (90%)   |
| <b>CARDIOVASCULAR SYSTEM</b>          |         |             |             |            |          |           |
| Blood Vessel                          | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Heart                                 | (10)    | (10)        | (10)        | (10)       | (10)     | (10)      |
| Cardiomyopathy                        | 9 (90%) | 8 (80%)     | 8 (80%)     | 9 (90%)    | 7 (70%)  | 7 (70%)   |
| Mineralization                        | 1 (10%) |             |             | 1 (10%)    |          | 6 (60%)   |
| Myocardium, Pigmentation, Hemosiderin | 1 (10%) |             |             |            |          |           |
| <b>ENDOCRINE SYSTEM</b>               |         |             |             |            |          |           |
| Adrenal Cortex                        | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Accessory Adrenal Cortical Nodule     |         |             |             |            |          | 1 (10%)   |
| Capsule, Fibrosis                     | 1 (10%) |             |             |            |          |           |
| Adrenal Medulla                       | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Islets, Pancreatic                    | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Parathyroid Gland                     | (10)    | (0)         | (0)         | (0)        | (0)      | (9)       |
| Pituitary Gland                       | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Chromophobe CL, Hyperplasia           | 1 (10%) |             |             |            |          |           |
| Thyroid Gland                         | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Cyst                                  |         |             |             |            |          | 1 (10%)   |
| <b>GENERAL BODY SYSTEM</b>            |         |             |             |            |          |           |
| None                                  |         |             |             |            |          |           |
| <b>GENITAL SYSTEM</b>                 |         |             |             |            |          |           |
| Epididymis                            | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Inflammation, Granulomatous           |         |             |             |            |          | 1 (10%)   |
| Preputial Gland                       | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Infiltration Cellular, Mononuclear CI |         |             |             |            |          | 1 (10%)   |
| Inflammation, Chronic Active          |         |             |             |            |          | 2 (20%)   |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99020-03

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: Pulegone

Time Report Requested: 05:19:07

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: BAT

| F 344/N Rat MALE                                | 0 MG/KG | 9.375 MG/KG | 18.75 MG/KG | 37.5 MG/KG | 75 MG/KG  | 150 MG/KG |
|---|---------|-------------|-------------|------------|-----------|-----------|
| Inflammation, Suppurative Prostate              | 1 (10%) | (0)         | (0)         | (0)        | (0)       | (10)      |
| Inflammation, Suppurative Seminal Vesicle       | (10)    | (0)         | (0)         | (0)        | (0)       | 1 (10%)   |
| Testes  | (10)    | (2)         | (0)         | (0)        | (0)       | (10)      |
| Germinal Epith, Degeneration                    |         | 2 (100%)    |             |            |           |           |
| <b>HEMATOPOIETIC SYSTEM</b>                     |         |             |             |            |           |           |
| Bone Marrow                                     | (10)    | (10)        | (10)        | (10)       | (10)      | (10)      |
| Hyperplasia                                     | 3 (30%) | 1 (10%)     | 5 (50%)     | 9 (90%)    | 10 (100%) | 10 (100%) |
| Lymph Node                                      | (1)     | (0)         | (0)         | (0)        | (0)       | (0)       |
| Lymph Node, Mesenteric                          | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Necrosis, Lymphoid                              |         |             |             |            |           | 1 (10%)   |
| Spleen  | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Thymus  | (10)    | (0)         | (0)         | (10)       | (10)      | (10)      |
| Atrophy   | 2 (20%) |             |             |            | 1 (10%)   | 1 (10%)   |
| <b>INTEGUMENTARY SYSTEM</b>                     |         |             |             |            |           |           |
| Mammary Gland                                   | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Skin  | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| <b>MUSCULOSKELETAL SYSTEM</b>                   |         |             |             |            |           |           |
| Bone  | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| <b>NERVOUS SYSTEM</b>                           |         |             |             |            |           |           |
| Brain   | (10)    | (10)        | (10)        | (10)       | (10)      | (10)      |
| <b>RESPIRATORY SYSTEM</b>                       |         |             |             |            |           |           |
| Lung  | (10)    | (10)        | (10)        | (10)       | (10)      | (10)      |
| Infiltration Cellular, Histiocyte               | 6 (60%) |             | 5 (50%)     | 4 (40%)    | 2 (20%)   | 8 (80%)   |
| Interstitial, Infiltration Cellular, Lymphocyte | 7 (70%) |             |             | 1 (10%)    | 2 (20%)   | 1 (10%)   |
| Nose  | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Trachea   | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99020-03

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: Pulegone

Time Report Requested: 05:19:07

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: BAT

| F 344/N Rat MALE                  | 0 MG/KG | 9.375 MG/KG | 18.75 MG/KG | 37.5 MG/KG | 75 MG/KG | 150 MG/KG |
|-----------------------------------|---------|-------------|-------------|------------|----------|-----------|
| <b>SPECIAL SENSES SYSTEM</b>      |         |             |             |            |          |           |
| Eye                               | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Inflammation, Acute               |         |             |             |            |          | 1 (10%)   |
| Harderian Gland                   | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Inflammation, Acute               |         |             |             |            |          | 1 (10%)   |
| <b>URINARY SYSTEM</b>             |         |             |             |            |          |           |
| Kidney                            | (10)    | (10)        | (10)        | (10)       | (10)     | (10)      |
| Accumulation, Hyaline Droplet     | 3 (30%) |             | 1 (10%)     | 1 (10%)    |          |           |
| Glomerulopathy, Hyaline           |         |             |             |            | 2 (20%)  | 10 (100%) |
| Infiltration Cellular, Lymphocyte | 1 (10%) |             | 1 (10%)     | 1 (10%)    |          |           |
| Mineralization                    | 6 (60%) | 8 (80%)     | 8 (80%)     | 7 (70%)    | 9 (90%)  | 7 (70%)   |
| Renal Tubule, Casts Protein       | 7 (70%) | 4 (40%)     | 6 (60%)     | 6 (60%)    | 4 (40%)  | 10 (100%) |
| Renal Tubule, Regeneration        | 9 (90%) | 9 (90%)     | 10 (100%)   | 10 (100%)  | 3 (30%)  | 9 (90%)   |
| Urinary Bladder                   | (9)     | (0)         | (0)         | (0)        | (0)      | (10)      |
| Infiltration Cellular             | 1 (11%) |             |             |            |          |           |
| Mineralization                    |         |             |             |            |          | 1 (10%)   |

\*\*\*END OF MALE DATA\*\*\*

Experiment Number: 99020-03  
 Test Type: 90-DAY  
 Route: GAVAGE  
 Species/Strain: Rat/F 344/N

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
 Test Compound: Pulegone  
 CAS Number: 89-82-7

Date Report Requested: 10/20/2014  
 Time Report Requested: 05:19:07  
 First Dose M/F: NA / NA  
 Lab: BAT

| F 344/N Rat FEMALE               | 0 MG/KG | 9.375 MG/KG | 18.75 MG/KG | 37.5 MG/KG | 75 MG/KG | 150 MG/KG |
|----------------------------------|---------|-------------|-------------|------------|----------|-----------|
| <b>Disposition Summary</b>       |         |             |             |            |          |           |
| Animals Initially In Study       | 10      | 10          | 10          | 10         | 10       | 10        |
| Early Deaths                     |         |             |             |            |          |           |
| Natural Death                    |         |             |             |            |          | 1         |
| Survivors                        |         |             |             |            |          |           |
| Terminal Sacrifice               | 10      | 10          | 10          | 10         | 10       | 9         |
| Animals Examined Microscopically | 10      | 10          | 10          | 10         | 10       | 10        |
| <b>ALIMENTARY SYSTEM</b>         |         |             |             |            |          |           |
| Esophagus                        | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Inflammation, Chronic            | 1 (10%) |             |             |            |          |           |
| Intestine Large, Cecum           | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Intestine Large, Colon           | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Intestine Large, Rectum          | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Intestine Small, Duodenum        | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Intestine Small, Ileum           | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Intestine Small, Jejunum         | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Liver                            | (10)    | (10)        | (10)        | (10)       | (10)     | (10)      |
| Basophilic Focus                 | 1 (10%) |             |             |            |          |           |
| Bile Duct, Hyperplasia           |         |             |             |            | 1 (10%)  | 10 (100%) |
| Hepatocyte, Hypertrophy          |         |             |             |            |          | 10 (100%) |
| Hepatodiaphragmatic Nodule       | 1 (10%) | 2 (20%)     | 2 (20%)     | 2 (20%)    |          | 1 (10%)   |
| Inflammation, Chronic Active     |         | 1 (10%)     |             |            |          |           |
| Oval Cell, Hyperplasia           |         |             |             |            |          | 9 (90%)   |
| Periportal, Fibrosis             |         |             |             |            |          | 9 (90%)   |
| Serosa, Fibrosis                 | 1 (10%) |             |             |            |          |           |
| Pancreas                         | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Salivary Glands                  | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Stomach, Forestomach             | (10)    | (0)         | (0)         | (0)        | (0)      | (10)      |
| Stomach, Glandular               | (10)    | (10)        | (10)        | (10)       | (10)     | (10)      |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99020-03

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/20/2014

Test Type: 90-DAY

Test Compound: Pulegone

Time Report Requested: 05:19:07

Route: GAVAGE

CAS Number: 89-82-7

First Dose M/F: NA / NA

Species/Strain: Rat/F 344/N

Lab: BAT

| F 344/N Rat FEMALE           | 0 MG/KG | 9.375 MG/KG | 18.75 MG/KG | 37.5 MG/KG | 75 MG/KG  | 150 MG/KG |
|------------------------------|---------|-------------|-------------|------------|-----------|-----------|
| Mineralization               |         | 3 (30%)     | 2 (20%)     | 2 (20%)    | 6 (60%)   | 7 (70%)   |
| <b>CARDIOVASCULAR SYSTEM</b> |         |             |             |            |           |           |
| Blood Vessel                 | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Heart                        | (10)    | (10)        | (10)        | (10)       | (10)      | (10)      |
| Cardiomyopathy               | 6 (60%) | 3 (30%)     |             | 4 (40%)    | 5 (50%)   | 2 (20%)   |
| Mineralization               |         |             |             |            |           | 1 (10%)   |
| <b>ENDOCRINE SYSTEM</b>      |         |             |             |            |           |           |
| Adrenal Cortex               | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Adrenal Medulla              | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Islets, Pancreatic           | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Parathyroid Gland            | (9)     | (0)         | (0)         | (0)        | (0)       | (10)      |
| Pituitary Gland              | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Thyroid Gland                | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Cyst                         |         |             |             |            |           | 1 (10%)   |
| <b>GENERAL BODY SYSTEM</b>   |         |             |             |            |           |           |
| None                         |         |             |             |            |           |           |
| <b>GENITAL SYSTEM</b>        |         |             |             |            |           |           |
| Clitoral Gland               | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Inflammation, Chronic Active |         |             |             |            |           | 1 (10%)   |
| Ovary                        | (10)    | (10)        | (10)        | (10)       | (10)      | (10)      |
| Cyst                         | 1 (10%) | 2 (20%)     | 2 (20%)     | 2 (20%)    | 3 (30%)   | 6 (60%)   |
| Uterus                       | (10)    | (10)        | (10)        | (10)       | (10)      | (10)      |
| Dilatation                   | 2 (20%) |             |             |            |           |           |
| <b>HEMATOPOIETIC SYSTEM</b>  |         |             |             |            |           |           |
| Bone Marrow                  | (10)    | (10)        | (10)        | (10)       | (10)      | (10)      |
| Hyperplasia                  | 1 (10%) | 1 (10%)     | 1 (10%)     | 1 (10%)    | 10 (100%) | 9 (90%)   |
| Lymph Node, Mesenteric       | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |
| Spleen                       | (10)    | (0)         | (0)         | (0)        | (0)       | (10)      |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99020-03

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Rat/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Pulegone

CAS Number: 89-82-7

Date Report Requested: 10/20/2014

Time Report Requested: 05:19:07

First Dose M/F: NA / NA

Lab: BAT

| F 344/N Rat FEMALE  | 0 MG/KG            | 9.375 MG/KG | 18.75 MG/KG | 37.5 MG/KG | 75 MG/KG  | 150 MG/KG          |
|---|--------------------|-------------|-------------|------------|-----------|--------------------|
| Thymus Atrophy  | (10)<br>1 (10%)    | (0)         | (0)         | (0)        | (10)      | (10)               |
| INTEGUMENTARY SYSTEM  |                    |             |             |            |           |                    |
| Mammary Gland   | (10)               | (0)         | (0)         | (0)        | (0)       | (10)               |
| Skin  | (10)               | (0)         | (0)         | (0)        | (0)       | (10)               |
| MUSCULOSKELETAL SYSTEM  |                    |             |             |            |           |                    |
| Bone  | (10)               | (0)         | (0)         | (0)        | (0)       | (10)               |
| NERVOUS SYSTEM  |                    |             |             |            |           |                    |
| Brain   | (9)                | (10)        | (10)        | (10)       | (10)      | (10)               |
| Brain, Cerebellum   | (1)                | (0)         | (0)         | (0)        | (0)       | (0)                |
| Dysplasia   | 1 (100%)           |             |             |            |           |                    |
| RESPIRATORY SYSTEM  |                    |             |             |            |           |                    |
| Lung  | (10)               | (10)        | (10)        | (10)       | (10)      | (10)               |
| Infiltration Cellular, Histiocyte Interstitium, Infiltration Cellular, Lymphocyte | 1 (10%)<br>4 (40%) |             |             | 2 (20%)    | 2 (20%)   | 6 (60%)            |
| Nose  | (10)               | (0)         | (0)         | (0)        | (0)       | (10)               |
| Trachea   | (10)               | (0)         | (0)         | (0)        | (0)       | (10)               |
| SPECIAL SENSES SYSTEM   |                    |             |             |            |           |                    |
| Eye   | (10)               | (0)         | (0)         | (0)        | (0)       | (10)               |
| Harderian Gland   | (10)               | (0)         | (0)         | (0)        | (0)       | (10)               |
| URINARY SYSTEM  |                    |             |             |            |           |                    |
| Kidney  | (10)               | (10)        | (10)        | (10)       | (10)      | (10)               |
| Glomerulopathy, Hyaline Mineralization  | 6 (60%)            | 10 (100%)   | 9 (90%)     | 9 (90%)    | 10 (100%) | 8 (80%)<br>9 (90%) |
| Nephropathy   |                    |             |             |            |           | 1 (10%)            |
| Renal Tubule, Casts Protein   | 1 (10%)            |             |             |            | 2 (20%)   | 6 (60%)            |
| Renal Tubule, Regeneration  |                    | 1 (10%)     |             |            |           |                    |

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 99020-03

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: Rat/F 344/N

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

Test Compound: Pulegone

CAS Number: 89-82-7

Date Report Requested: 10/20/2014

Time Report Requested: 05:19:08

First Dose M/F: NA / NA

Lab: BAT

---

| <b>F 344/N Rat FEMALE</b> | <b>0 MG/KG</b> | <b>9.375 MG/KG</b> | <b>18.75 MG/KG</b> | <b>37.5 MG/KG</b> | <b>75 MG/KG</b> | <b>150 MG/KG</b> |
|---------------------------|----------------|--------------------|--------------------|-------------------|-----------------|------------------|
| Urinary Bladder           | (10)           | (0)                | (0)                | (0)               | (0)             | (10)             |
| Mineralization            | 1 (10%)        |                    |                    |                   |                 |                  |

---

**\*\* END OF REPORT \*\***